Sanofi (SNY)
NASDAQ: SNY · Real-Time Price · USD
45.95
+0.05 (0.11%)
At close: Apr 28, 2026, 4:00 PM EDT
45.52
-0.43 (-0.94%)
Pre-market: Apr 29, 2026, 7:10 AM EDT
Sanofi Revenue
Sanofi had revenue of 11.24B EUR in the quarter ending March 31, 2026, with 6.02% growth. This brings the company's revenue in the last twelve months to 47.35B, up 8.18% year-over-year. In the year 2025, Sanofi had annual revenue of 46.72B with 5.49% growth.
Revenue (ttm)
47.35B EUR
Revenue Growth
+8.18%
P/S Ratio
2.04
Revenue / Employee
632,686 EUR
Employees
74,846
Market Cap
111.55B USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 46.72B | 2.43B | 5.49% |
| Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
| Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
| Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
| Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Merck & Co. | 65.01B |
| Pfizer | 62.58B |
| AbbVie | 61.16B |
| AstraZeneca | 58.74B |
| Novartis AG | 56.67B |
| Novo Nordisk | 48.59B |
| Bristol-Myers Squibb Company | 48.19B |
| GSK plc | 43.97B |
SNY News
- 2 days ago - Sanofi Prices EUR 2.3 Bln Notes Offering Across Three Tranches - Nasdaq
- 4 days ago - 3 Healthcare Stocks That Pay You a Dividend While You Wait for a Recovery - The Motley Fool
- 4 days ago - Press Release: Sanofi successfully prices 2.3 billion of bond issue - GlobeNewsWire
- 4 days ago - Sanofi (SNY) Gains EMA's Support for Multiple Sclerosis Treatment - GuruFocus
- 5 days ago - Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses - Benzinga
- 5 days ago - Press Release: Sanofi's Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses - GlobeNewsWire
- 5 days ago - Sanofi SA (SNY) Q1 2026 Earnings Call Highlights: Strong Sales Growth and Strategic Developments - GuruFocus
- 5 days ago - Q1 2026 Sanofi SA Earnings Call Transcript - GuruFocus